Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label neoadjuvant study of JSKN003 alone or in combination for HER2-expressing breast cancer
CTR20254192Phase 2Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of anbenitamab repodatecan in breast cancer, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Oct 2025; status: active.
02
Drugs
anbenitamab repodatecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20254192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254192.